Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | EDNRB | P24530 | 3/20 | 0.39 |
| ▸ | EDNRA | P25101 | 3/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | NQO1 | P15559 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1262305 | 0.81 | NPC1 (0.41) | ELANEMAPTALDH1A1KDM4EEDNRB | |
| SCHEMBL6585306 | 0.78 | KCNA3 (0.42) | ELANEMAPTALDH1A1EDNRBEDNRA | |
| SCHEMBL7601695 | 0.76 | BRD4 (0.42) | MAPTALDH1A1KDM4ELMNABRD4 | |
| SCHEMBL6682822 | 0.75 | NR3C1 (0.45) | NR3C1PGR | |
| SCHEMBL23745469 | 0.74 | EDNRA (0.36) | LMNAEDNRBEDNRANR3C1BRD4 | |
| SCHEMBL29835122 | 0.74 | EDNRA (0.36) | LMNAEDNRBEDNRANR3C1BRD4 | |
| SCHEMBL22447134 | 0.74 | ACHE (0.49) | LMNANR3C1PGRKCNA3 | |
| SCHEMBL6554510 | 0.74 | NR3C1 (0.52) | ELANEALDH1A1KDM4ENR3C1PGR | |
| SCHEMBL5985206 | 0.74 | MAPT (0.53) | MAPTLMNABRD4 | |
| SCHEMBL4399692 | 0.74 | CHRNB2 (0.45) | MAPTALDH1A1KDM4EBRD4RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213452-A1 | CONDITIONALLY ACTIVE HETERODIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-07-07 | — | — | US | disclosed |
| US-11136562-B2 | Conditionally active heterodimeric polypeptides and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-05 | — | — | US | disclosed |
| US-20170306303-A1 | CONDITIONALLY ACTIVE HETERODIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-10-26 | — | — | US | disclosed |
| US-20170306303-A1 | CONDITIONALLY ACTIVE HETERODIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-10-26 | — | — | US | disclosed |
| WO-2009071252-A1 | NONSTEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-11 | — | — | WO | disclosed |
| US-7388006-B2 | Non-steroidal progesting | BAYER SCHERING PHARMA AG (DE) | 2008-06-17 | — | — | US | disclosed |
| US-7388006-B2 | Non-steroidal progesting | BAYER SCHERING PHARMA AG (DE) | 2008-06-17 | — | — | US | disclosed |
| US-7189758-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189758-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| WO-2007022824-A1 | USE OF NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-01 | — | — | WO | disclosed |
| EP-1482925-B1 | 5-(2-HYDROXY-3-'1-(3-TRIFLUOROMETHYLPHENYL)-CYCLOPROPL]-PROPIONYLAMINO)-PHTALIDE AND RELATED COMPOUNDS WITH PROGESTERONE RECEPTOR MODULATING ACTIVITY FOR USE IN FERTILITY CONTROL AND HORMONE REPLACEMENT THERAPY | SCHERING AG (DE) | 2007-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136562-B2 | Conditionally active heterodimeric polypeptides and methods of use thereof | CPB2, AGBL2, IAPP | ELANE 454/4885MAPT 4444/4885ALDH1A1 4013/4885 |
| US-20220213452-A1 | CONDITIONALLY ACTIVE HETERODIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | CPB2, AGBL2, IAPP | ELANE 454/4885MAPT 4444/4885ALDH1A1 4013/4885 |
| US-20170306303-A1 | CONDITIONALLY ACTIVE HETERODIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF | CPB2, AGBL2, IAPP | ELANE 454/4885MAPT 4444/4885ALDH1A1 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.